172 related articles for article (PubMed ID: 20194881)
1. Effect of rosiglitazone on progression of coronary atherosclerosis in patients with type 2 diabetes mellitus and coronary artery disease: the assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history trial.
Gerstein HC; Ratner RE; Cannon CP; Serruys PW; García-García HM; van Es GA; Kolatkar NS; Kravitz BG; Miller DM; Huang C; Fitzgerald PJ; Nesto RW;
Circulation; 2010 Mar; 121(10):1176-87. PubMed ID: 20194881
[TBL] [Abstract][Full Text] [Related]
2. Assessment on the Prevention of Progression by Rosiglitazone on Atherosclerosis in diabetes patients with Cardiovascular History (APPROACH): study design and baseline characteristics.
Ratner RE; Cannon CP; Gerstein HC; Nesto RW; Serruys PW; Van Es GA; Kolatkar NS; Kravitz BG; Zalewski A; Fitzgerald PJ;
Am Heart J; 2008 Dec; 156(6):1074-9. PubMed ID: 19033001
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of in-stent restenosis in the APPROACH trial (Assessment on the Prevention of Progression by Rosiglitazone On Atherosclerosis in diabetes patients with Cardiovascular History).
García-García HM; Garg S; Brugaletta S; Morocutti G; Ratner RE; Kolatkar NS; Kravitz BG; Miller DM; Huang C; Nesto RW; Serruys PW;
Int J Cardiovasc Imaging; 2012 Mar; 28(3):455-65. PubMed ID: 21359834
[TBL] [Abstract][Full Text] [Related]
4. A multicentre, randomized, double-blind placebo-controlled trial evaluating rosiglitazone for the prevention of atherosclerosis progression after coronary artery bypass graft surgery in patients with type 2 diabetes. Design and rationale of the VeIn-Coronary aTherOsclerosis and Rosiglitazone after bypass surgerY (VICTORY) trial.
Bertrand OF; Poirier P; Rodés-Cabau J; Rinfret S; Title L; Dzavik V; Natarajan M; Angel J; Batalla N; Alméras N; Costerousse O; De Larochellière R; Roy L; Després JP;
Can J Cardiol; 2009 Sep; 25(9):509-15. PubMed ID: 19746240
[TBL] [Abstract][Full Text] [Related]
5. Lowering the triglyceride/high-density lipoprotein cholesterol ratio is associated with the beneficial impact of pioglitazone on progression of coronary atherosclerosis in diabetic patients: insights from the PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation) study.
Nicholls SJ; Tuzcu EM; Wolski K; Bayturan O; Lavoie A; Uno K; Kupfer S; Perez A; Nesto R; Nissen SE
J Am Coll Cardiol; 2011 Jan; 57(2):153-9. PubMed ID: 21211686
[TBL] [Abstract][Full Text] [Related]
6. Effect of rosiglitazone on progression of atherosclerosis: insights using 3D carotid cardiovascular magnetic resonance.
Varghese A; Yee MS; Chan CF; Crowe LA; Keenan NG; Johnston DG; Pennell DJ
J Cardiovasc Magn Reson; 2009 Jul; 11(1):24. PubMed ID: 19635160
[TBL] [Abstract][Full Text] [Related]
7. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial.
Nissen SE; Nicholls SJ; Wolski K; Nesto R; Kupfer S; Perez A; Jure H; De Larochellière R; Staniloae CS; Mavromatis K; Saw J; Hu B; Lincoff AM; Tuzcu EM;
JAMA; 2008 Apr; 299(13):1561-73. PubMed ID: 18378631
[TBL] [Abstract][Full Text] [Related]
8. Rosiglitazone and outcomes for patients with diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.
Bach RG; Brooks MM; Lombardero M; Genuth S; Donner TW; Garber A; Kennedy L; Monrad ES; Pop-Busui R; Kelsey SF; Frye RL;
Circulation; 2013 Aug; 128(8):785-94. PubMed ID: 23857320
[TBL] [Abstract][Full Text] [Related]
9. Effect of rosiglitazone on restenosis after coronary stenting in patients with type 2 diabetes.
Osman A; Otero J; Brizolara A; Waxman S; Stouffer G; Fitzgerald P; Uretsky BF
Am Heart J; 2004 May; 147(5):e23. PubMed ID: 15131558
[TBL] [Abstract][Full Text] [Related]
10. Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.
Derosa G; Cicero AF; D'Angelo A; Gaddi A; Ciccarelli L; Piccinni MN; Salvadeo SA; Pricolo F; Ferrari I; Gravina A; Ragonesi PD
Clin Ther; 2006 May; 28(5):679-88. PubMed ID: 16861090
[TBL] [Abstract][Full Text] [Related]
11. Cardiometabolic effects of rosiglitazone in patients with type 2 diabetes and coronary artery bypass grafts: A randomized placebo-controlled clinical trial.
Bertrand OF; Poirier P; Rodés-Cabau J; Rinfret S; Title LM; Dzavik V; Natarajan M; Angel J; Batalla N; Alméras N; Costerousse O; De Larochellière R; Roy L; Després JP;
Atherosclerosis; 2010 Aug; 211(2):565-73. PubMed ID: 20594555
[TBL] [Abstract][Full Text] [Related]
12. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial.
Nissen SE; Tuzcu EM; Schoenhagen P; Brown BG; Ganz P; Vogel RA; Crowe T; Howard G; Cooper CJ; Brodie B; Grines CL; DeMaria AN;
JAMA; 2004 Mar; 291(9):1071-80. PubMed ID: 14996776
[TBL] [Abstract][Full Text] [Related]
13. Sitagliptin attenuates the progression of coronary atherosclerosis in patients with coronary disease and type 2 diabetes.
Li B; Luo YR; Tian F; Chen YD; Tian JW; Ding Y; Zhu M; Li JW; Zhang YQ; Shi WM
Atherosclerosis; 2020 May; 300():10-18. PubMed ID: 32247073
[TBL] [Abstract][Full Text] [Related]
14. Reduction in use of healthcare services with combination sulfonylurea and rosiglitazone: findings from the Rosiglitazone Early vs SULfonylurea Titration (RESULT) study.
Herman WH; Dirani RG; Horblyuk R; O'Neill MC; Kravitz B; Heise MA; Bakst A; Freed MI;
Am J Manag Care; 2005 Apr; 11(4):273-8. PubMed ID: 15839187
[TBL] [Abstract][Full Text] [Related]
15. Multiple risk factor intervention and progression of coronary atherosclerosis in patients with type 2 diabetes mellitus.
Kataoka Y; Shao M; Wolski K; Uno K; Puri R; Tuzcu EM; Nissen SE; Nicholls SJ
Eur J Prev Cardiol; 2013 Apr; 20(2):209-17. PubMed ID: 22345692
[TBL] [Abstract][Full Text] [Related]
16. Effect of early addition of rosiglitazone to sulphonylurea therapy in older type 2 diabetes patients (>60 years): the Rosiglitazone Early vs. SULphonylurea Titration (RESULT) study.
Rosenstock J; Goldstein BJ; Vinik AI; O'neill MC; Porter LE; Heise MA; Kravitz B; Dirani RG; Freed MI;
Diabetes Obes Metab; 2006 Jan; 8(1):49-57. PubMed ID: 16367882
[TBL] [Abstract][Full Text] [Related]
17. Effect of rosiglitazone on survival in patients with diabetes mellitus treated for coronary artery disease.
Choy-Shan A; Zinn A; Shah B; Danoff A; Donnino R; Schwartzbard AZ; Lorin JD; Grossi E; Sedlis SP
Coron Artery Dis; 2012 Aug; 23(5):354-8. PubMed ID: 22750913
[TBL] [Abstract][Full Text] [Related]
18. Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.
Roberts VL; Stewart J; Issa M; Lake B; Melis R
Clin Ther; 2005 Oct; 27(10):1535-47. PubMed ID: 16330290
[TBL] [Abstract][Full Text] [Related]
19. Effect of Serial Infusions of CER-001, a Pre-β High-Density Lipoprotein Mimetic, on Coronary Atherosclerosis in Patients Following Acute Coronary Syndromes in the CER-001 Atherosclerosis Regression Acute Coronary Syndrome Trial: A Randomized Clinical Trial.
Nicholls SJ; Andrews J; Kastelein JJP; Merkely B; Nissen SE; Ray KK; Schwartz GG; Worthley SG; Keyserling C; Dasseux JL; Griffith L; Kim SW; Janssan A; Di Giovanni G; Pisaniello AD; Scherer DJ; Psaltis PJ; Butters J
JAMA Cardiol; 2018 Sep; 3(9):815-822. PubMed ID: 30046828
[TBL] [Abstract][Full Text] [Related]
20. Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial.
Derosa G; Cicero AF; Gaddi AV; Ciccarelli L; Piccinni MN; Salvadeo S; Pricolo F; Fogari E; Ghelfi M; Ferrari I; Fogari R
Clin Ther; 2005 Sep; 27(9):1383-91. PubMed ID: 16291411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
